标题
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward
作者
关键词
-
出版物
PEDIATRIC DRUGS
Volume 25, Issue 6, Pages 635-647
出版商
Springer Science and Business Media LLC
发表日期
2023-09-30
DOI
10.1007/s40272-023-00594-7
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)
- (2023) Antonio Torrelo et al. BRITISH JOURNAL OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
- (2023) Eric F Morand et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)
- (2023) Michelle Petri et al. LANCET
- Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis
- (2023) Amy S. Paller et al. JAMA Dermatology
- JAK inhibitors in systemic juvenile idiopathic arthritis
- (2023) Tingyan He et al. Frontiers in Pediatrics
- Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
- (2023) Athimalaipet V Ramanan et al. LANCET
- The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS
- (2022) Kader Cetin Gedik et al. ANNALS OF THE RHEUMATIC DISEASES
- Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
- (2022) Yoshiya Tanaka et al. Nature Reviews Rheumatology
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- (2022) Hassiel Aurelio Ramírez-Marín et al. Drug Design Development and Therapy
- Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
- (2022) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations—10 Children and Review of the Literature
- (2022) Angela Deyà-Martínez et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Two Phase 3 Trials of Baricitinib for Alopecia Areata
- (2022) Brett King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
- (2022) Eric L. Simpson et al. JAMA Dermatology
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
- (2022) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibitors in difficult-to-treat adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis
- (2022) Louise Gillard et al. RHEUMATOLOGY
- A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
- (2022) Thomas Bieber et al. ADVANCES IN THERAPY
- JAK-STAT signaling pathway in non-infectious uveitis
- (2022) Yuhan Su et al. BIOCHEMICAL PHARMACOLOGY
- Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis
- (2022) Brad D. Constant et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
- (2021) Bernard Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
- (2021) Camille Keenan et al. Frontiers in Immunology
- Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
- (2021) Claudia Schinocca et al. Frontiers in Immunology
- Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
- (2021) Atul Deodhar et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of Pediatric Alopecia Areata: A Systematic Review
- (2021) Virginia R. Barton et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
- (2021) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review
- (2021) Pedro Jesús Gómez-Arias et al. Dermatology and Therapy
- Current and future status of JAK inhibitors
- (2021) Donal P McLornan et al. LANCET
- Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
- (2021) Brian G Feagan et al. LANCET
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial
- (2021) Vincent C Marconi et al. Lancet Respiratory Medicine
- Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial
- (2021) Nicolino Ruperto et al. LANCET
- Tofacitinib in juvenile idiopathic arthritis
- (2021) Sarah L N Clarke et al. LANCET
- JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology
- (2021) Meredyth G. Ll Wilkinson et al. Pediatric Rheumatology
- Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
- (2021) Athimalaipet V. Ramanan et al. Trials
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis
- (2020) Elisabetta Miserocchi et al. CLINICAL RHEUMATOLOGY
- Ruxolitinib salvage therapy is effective for steroid‐refractory graft‐versus‐host disease in children: A single‐center experience
- (2020) Vedat Uygun et al. PEDIATRIC BLOOD & CANCER
- Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children
- (2020) Ang Wei et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Janus Kinase Inhibition in the Aicardi–Goutières Syndrome
- (2020) Adeline Vanderver et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
- (2020) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
- (2020) Josef S Smolen et al. RHEUMATOLOGY
- Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis
- (2019) Peter C. Taylor et al. Arthritis & Rheumatology
- Janus kinases to jakinibs: from basic insights to clinical practice
- (2019) Massimo Gadina et al. RHEUMATOLOGY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis
- (2019) Zhixiang Huang et al. PEDIATRICS
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Fatal encephalopathy with wild‐type JC virus and ruxolitinib therapy
- (2019) Lauren Bowen Reoma et al. ANNALS OF NEUROLOGY
- Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation
- (2019) Kesavan Melarcode Ramanan et al. PEDIATRIC BLOOD & CANCER
- Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
- (2019) Désirée van der Heijde et al. LANCET
- Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
- (2018) G.J. Schmieder et al. BRITISH JOURNAL OF DERMATOLOGY
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
- (2018) Josef S. Smolen et al. JOURNAL OF RHEUMATOLOGY
- Clinical significance of Janus Kinase inhibitor selectivity
- (2018) Ernest H Choy RHEUMATOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Familial chilblain lupus due to a gain-of-function mutation in STING
- (2016) Nadja König et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
- (2012) Y Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pathogenesis of Rheumatoid Arthritis
- (2011) Iain B. McInnes et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started